By Bhanvi Satija LONDON, Feb 2 (Reuters) - French drugmaker Sanofi said on Monday that its experimental genetic disorder ...

Feb 2 (Reuters) - Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more ...

The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth ...

The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of ...

Regeneron (REGN) stock in focus as the company posts Q4 2025 beat as its revenue tied to Sanofi (SNY) partnership offsets headwinds to Eylea franchise. Read more here.

This vaccine-focused biotech reported a significant insider sale as it advances its hepatitis B franchise and global ...

LONDON, Jan 29 (Reuters) - French drugmaker Sanofi said on Thursday it expects sales to grow by a high-single-digit ...

Sanofi (SNY) shares traded slightly lower in Paris on Thursday even as the French drugmaker reported higher-than-expected ...

UK regulators ruled Sanofi breached industry rules over RSV claims in a newspaper interview, following a complaint from ...

Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the ...

Both products can be used in the UK to provide protection against RSV disease in certain settings. Abrysvo was cleared for ...

Venglustat is designed to reduce the toxic build-up, and the new trial showed that a daily dose of the drug achieved ...